Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366042 | 0.81 | APOBEC3G (0.31) | APOBEC3G | |
| SCHEMBL249080 | 0.76 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL11172021 | 0.75 | MEN1 (0.43) | MEN1KMT2AAPOBEC3G | |
| SCHEMBL2558474 | 0.72 | MCHR1 (0.42) | MEN1KMT2A | |
| SCHEMBL28048096 | 0.72 | RAB9A (0.42) | MEN1KMT2A | |
| SCHEMBL10509688 | 0.68 | MTNR1A (0.50) | MEN1KMT2A | |
| SCHEMBL11954594 | 0.68 | CYP1A2 (0.62) | MEN1KMT2A | |
| SCHEMBL22650245 | 0.68 | KMT2A (0.37) | MEN1KMT2A | |
| SCHEMBL946878 | 0.66 | ALDH1A1 (0.52) | — | |
| SCHEMBL7523014 | 0.65 | APOBEC3G (0.35) | APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2013048811-A1 | IMAGING AND RADIOTHERAPY METHODS FOR TUMOUR STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013048832-A1 | 18 F - LABELLED 6 - ( 2 - FLUOROETHOXY) - 2 - NAPHTHALDEHYDE FOR DETECTING CANCER STEM CELLS | GE HEALTHCARE LIMITED (GB) | 2013-04-04 | — | — | WO | disclosed |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | GENERAL ELECTRIC COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2349351-A2 | IMAGING AND RADIOTHERAPY METHODS | GE Healthcare Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010048144-A2 | IMAGING AND RADIOTHERAPY METHODS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101509-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | MEN1 2884/4885KMT2A 1972/4885APOBEC3G 343/4885 |
| US-20110286922-A1 | IMAGING AND RADIOTHERAPY METHODS | ALDH2, ALDH3A1, ALDH1A1 | MEN1 2884/4885KMT2A 1972/4885APOBEC3G 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.